# Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

> **NCT03450057** · PHASE2 · COMPLETED · sponsor: **Hellenic Society of Hematology** · enrollment: 38 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab with dexamethasone

## Key facts

- **NCT ID:** NCT03450057
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-15
- **Primary completion:** 2021-03-22
- **Final completion:** 2021-03-22
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450057, "Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03450057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*